This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Is it a Good Idea to Invest in Immunocore Stock Right Now?
by Zacks Equity Research
IMCR is seeing strong Kimmtrak sales growth and pursuing label expansion studies that could broaden its reach across melanoma treatments.
BMYNegative Net Change LQDAPositive Net Change IMCRNegative Net Change
biotechs
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
by Zacks Equity Research
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
INCYNegative Net Change LQDAPositive Net Change MIRMPositive Net Change IMCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can BMY's Camzyos Strengthen Its Cardiovascular Portfolio?
by Zacks Equity Research
Bristol Myers eyes growth from Camzyos as the FDA reviews its use in adolescents with obstructive HCM, expanding the drug's market reach.
BMYNegative Net Change JNJNegative Net Change CYTKNegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV Prevention
by Zacks Equity Research
Gilead seeks FDA approval for once-weekly oral Yeztugo for HIV prevention, aiming to expand access with a new long-acting PrEP option.
GSKNegative Net Change MRKNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Accepts AstraZeneca's Filing for Expanded Use of Ultomiris
by Zacks Equity Research
AZN's Ultomiris wins FDA priority review for IgAN, backed by late-stage data showing a 43.4% proteinuria reduction versus placebo.
AZNNegative Net Change NVSNegative Net Change TVTXPositive Net Change
biotechs medical pharmaceuticals
NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up
by Zacks Equity Research
Intellia jumps after additional phase III HAELO data showed lonvo-z cut on-demand-treated attacks by 89% and moderate-to-severe episodes by 91%.
NTLAPositive Net Change LQDAPositive Net Change KNSAPositive Net Change IMCRNegative Net Change
biotechs
ALKS' Sleep Disorder Drug Gets Orphan Drug Tags in the U.S. & Europe
by Zacks Equity Research
Alkermes wins orphan drug designations in the United States and Europe for alixorexton for treating idiopathic hypersomnia and narcolepsy, respectively.
ALKSNegative Net Change LQDAPositive Net Change KNSAPositive Net Change IMCRNegative Net Change
biotechs
Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure
by Zacks Equity Research
NMRA stock sinks 49% after phase III depression studies show navacaprant's failure to meet key goals, leading to discontinuation of its development.
LQDAPositive Net Change IMCRNegative Net Change INDVPositive Net Change NMRANegative Net Change
biotechnology biotechs medical pharmaceuticals
Beam Therapeutics Stock Soars 21% in Three Months: Here's Why
by Zacks Equity Research
BEAM shares jump 21% in three months as promising BEAM-302 data, pipeline milestones and a cash runway into mid-2029 boost investor confidence.
BEAMPositive Net Change LQDAPositive Net Change IMCRNegative Net Change INDVPositive Net Change
biotechs
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
by Zacks Equity Research
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
INCYNegative Net Change LQDAPositive Net Change MIRMPositive Net Change IMCRNegative Net Change
biotechnology biotechs medical pharmaceuticals